Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Neoplasms, Breast
Interventions
Immunotherapeutic SB719125 (Primary)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Boca Raton, Florida • Buffalo, New York • Charlotte, North Carolina + 1 more
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

NCT01427309
Conditions
Influenza
Interventions
High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
31,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
105
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Conditions
Glioblastoma
Interventions
Cyclophosphamide, IMA950 plus GM-CSF, IMA950, Imiquimod
Drug · Biological
Lead sponsor
Immatics Biotechnologies GmbH
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Marburg Virus Disease
Interventions
rVSV∆G-MARV-GP, Placebo
Biological · Other
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Lenexa, Kansas
Conditions
Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions
Metformin, Placebo, Jynneos, Capvaxvie
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Early Phase 1 Interventional Accepts healthy volunteers

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736
Conditions
Substance Use Disorders
Interventions
Entolimod, Td Vaccine
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Conditions
COVID-19
Interventions
Active Intervention Group
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Melanoma
Interventions
tvs-CTL Vaccine
Biological
Lead sponsor
Gary Doolittle
Other
Eligibility
18 Years to 66 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Fairway, Kansas
Conditions
Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions
Drug: Hyperacute Lung Cancer Cell Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Human Papillomavirus Infection
Interventions
VACs
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Albany, New York • Madison, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

NCT01173211
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
5
States / cities
St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more
Conditions
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions
Mammaglobin-A DNA Vaccine, Optional biopsy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions
blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

NCT05973006
Conditions
COVID-19
Interventions
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Biological
Lead sponsor
Novavax
Industry
Eligibility
11 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Davie, Florida • Jacksonville, Florida • Miami, Florida + 17 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

NCT00000904
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2, ALVAC(1)120(B,MN)GNP (vCP1433), ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Completed No phase listed Observational Accepts healthy volunteers Results available

The Psychoneuroimmunology of Insomnia

NCT00680771
Conditions
Primary Insomnia
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, New York
Conditions
Alzheimer's Disease
Interventions
CAD106, Placebo, Alum, MF59
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 85 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more